According to GlobalData’s medical device pipeline database, 144 Inflammatory Disease Markers devices are in various stages of development globally. GlobalData’s report Inflammatory Disease Markers provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 74 are in active development, while the remaining 70 are in an inactive stage of development. There are 51 products in the early stages of development, and the remaining 23 are in the late stages of development.
The inflammatory disease markers existing in the body help in detection and monitoring of the inflammatory diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus, as well as monitoring inflammation in patients not related to chronic disease. In RA patients, markers like Rheumatoid Factor (RF), C-reactive protein (CRP), and anti-cyclic citrullinated peptide (CCP) antibodies play a major role in diagnosis and monitoring of the disease. The two major techniques that are used for detection are analyzer dependent techniques, such as Enzyme Linked Immuno Sorbent Assay (ELISA), Nephelometry, Radioimmunoassay (RIA) technique and the analyzer independent, Latex Agglutination technique. This sub-segment includes analyzer dependent and analyzer independent techniques based tests for Rheumatoid Factor (RF), C-reactive protein (CRP), Procalcitonin and Anti-Cyclic Citrullinated Peptide (CCP) Antibody.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Inflammatory Disease Markers pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Inflammatory Disease Markers devices. Overall, most of these Inflammatory Disease Markers pipeline devices are being developed by private entities.
Key players involved in the active development of Inflammatory Disease Markers include Siemens Healthcare Diagnostics, Beckman Coulter, Singulex, Guangzhou Wondfo Biotech, University of Manchester, Svar Life Science, Ortho Clinical Diagnostics, ELITechGroup, Queen Mary University of London and Roche Diagnostics.
For a complete picture of the developmental pipeline for Inflammatory Disease Markers devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
